Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.57 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.57 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.54 |
| ▸ | IL23R | Q5VWK5 | 11/20 | 0.53 |
| ▸ | TFPI | P10646 | 1/20 | 0.53 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.53 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31243862 | 0.97 | OPRD1 (0.58) | OPRM1OPRD1OPRK1IL23RTFPI | |
| SCHEMBL31243884 | 0.97 | OPRD1 (0.57) | OPRM1OPRD1OPRK1IL23ROPRL1 | |
| SCHEMBL31243858 | 0.94 | TFPI (0.55) | OPRM1OPRD1OPRK1IL23RTFPI | |
| SCHEMBL31243925 | 0.94 | TFPI (0.60) | OPRM1OPRD1OPRK1IL23RTFPI | |
| SCHEMBL31243874 | 0.93 | OPRD1 (0.62) | OPRM1OPRD1OPRK1 | |
| SCHEMBL31243861 | 0.92 | OPRD1 (0.62) | OPRM1OPRD1OPRK1TFPI | |
| SCHEMBL31243876 | 0.92 | OPRD1 (0.58) | OPRM1OPRD1OPRK1IL23ROPRL1 | |
| SCHEMBL31243945 | 0.92 | OPRD1 (0.56) | OPRM1OPRD1OPRK1IL23RTFPI | |
| SCHEMBL31243882 | 0.92 | KISS1R (0.54) | OPRM1OPRD1OPRK1IL23R | |
| SCHEMBL31243949 | 0.91 | OPRD1 (0.61) | OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263393-A1 | FAP INHIBITORS | SHANGHAI SINOTAU BIOTECH. CO., LTD (CN) | 2025-08-21 | — | — | US | disclosed |
| CN-120202191-A | Inhibitors of prostate specific membrane antigen and uses thereof | 上海先通生物科技有限公司 | 2025-06-24 | — | — | CN | disclosed |
| CN-119072472-A | FAP inhibitors | 上海先通生物科技有限公司 | 2024-12-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250263393-A1 | FAP INHIBITORS | FAP, APC, FIBP | OPRM1 4813/4885OPRD1 4807/4885OPRK1 4852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.